PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
Andrew Kuykendall,
Terrence Bradley,
Rami S. Komrokji,
Tymara Berry,
Souria Dougherty,
Laurie Sherman,
Lixian Peng,
Fei Huang,
Ying Wan,
Vivian Rodolf,
Judy Ho,
Shyamala Navada,
John Mascarenhas
Affiliations
Andrew Kuykendall
1 Moffitt Cancer Center, Tampa, United States
Terrence Bradley
2 Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, United States
Rami S. Komrokji
1 Moffitt Cancer Center, Tampa, United States
Tymara Berry
3 Geron Corporation, Parsippany, United States
Souria Dougherty
3 Geron Corporation, Parsippany, United States
Laurie Sherman
3 Geron Corporation, Parsippany, United States
Lixian Peng
3 Geron Corporation, Parsippany, United States
Fei Huang
3 Geron Corporation, Parsippany, United States
Ying Wan
3 Geron Corporation, Parsippany, United States
Vivian Rodolf
3 Geron Corporation, Parsippany, United States
Judy Ho
3 Geron Corporation, Parsippany, United States
Shyamala Navada
3 Geron Corporation, Parsippany, United States
John Mascarenhas
4 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States
